Abbott India Limited

ABBOTINDIA

INE358A01014

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 02:33:26 08/07/2025 pm IST			5-day change	1st Jan Change
34,097.45 ^INR	-1.05%		-1.73%	+14.63%

15/05	Abbott India's quarterly profit climbs 28% on strong demand	RE
15/05	Abbott India Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025	CI

Abbott India Limited Announces Resignation of Jyoti Saraph, Director Finance, with Effect from June 23, 2025

Published on 26/03/2025 at 15:46

Abbott India Limited informed that Ms. Jyoti Saraph, Director Finance, has tendered her resignation from employment of the Company with effect from the close of business hours of June 23, 2025, to pursue opportunities outside the Company.

Latest news about Abbott India Limited

Abbott India's quarterly profit climbs 28% on strong demand	15/05	RE
Abbott India Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025	15/05	CI
Abbott India Says Swati Dalal Resigns As Managing Director	07/05	RE
Abbott India Limited Announces Resignation of Swati Dalal as Managing Director, Effective June 13, 2025	07/05	CI
Abbott India Limited Announces Resignation of Swati Dalal as Director and Key Managerial Personnel, Effective June 13, 2025	07/05	CI
Abbott India Appoints Maithilee Mistry As CFO	18/04	RE
Abbott India Limited Appoints Maithilee Mistry as the Chief Financial Officer, Effective May 6, 2025	18/04	CI
Abbott India Limited Appoints Maithilee Mistry as the Key Managerial Personnel, Effective May 6, 2025	18/04	CI
Abbott India Limited Announces the Resignation of Ms. Namita Shah - Associate Director -New Product Introduction and Therapy Area Strategy of the Company, Effective from April 15, 2025	16/04	CI
Abbott India hits all-time high on robust Q3 25 performance	04/04
Abbott India Limited Appoints Devesh Choudhari as Director - Finance, Effective April 1, 2025	01/04	CI
Abbott India Limited Announces Resignation of Jyoti Saraph, Director Finance, with Effect from June 23, 2025	26/03	CI
Abbott India Limited Announces Resignation of Namita Shah - Associate Director - New Product Introduction and Therapy Area Strategy, Effective April 15, 2025	20/02	CI
Abbott India posts higher Q3 profit on strong demand	05/02	RE
Abbott India Q3 Profit 3.61 Bln Rupees	05/02	RE
Abbott India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	05/02	CI
Abbott India Limited Approves the Appointment of Harshraj Madan as Commercial Director - GI Business, Effective February 17, 2025	05/02	CI
Abbott India Limited Announces Board Changes	03/02	CI
Abbott India Limited Announces Kunal Chowdhury - Commercial Director - GI Businesses, to Serve Until January 31, 2025	21/01	CI
Abbott India Limited Appoints Anuj Mehra as Commercial Director - Neurolife, Gennext and Vaccines, Effective February 1, 2025	16/01	CI
Abbott India Limited Announces Change of Commercial Director	03/01	CI
Abbott India's CFO Steps Down	17/12	MT
Abbott India Limited Announces Resignation of Sridhar Kadangode as Whole Time Director and Director	16/12	CI
Abbott India Limited Announces Resignation of Sridhar Kadangode as Chief Financial Officer, Effective from February 26, 2025	16/12	CI
Abbott India Limited Appoints Mr. Sridhar Kadangode as an Additional Director and as the Whole Time Director of the Company	07/11	CI

Chart Abbott India Limited

Duration

Period

ABBOTINDIA: Dynamic Chart

Company Profile

Abbott India Limited is an India-based company engaged in the pharmaceuticals business. The Company is involved in product development, manufacturing, and sales of healthcare products. It operates in a single reportable business segment, which is Pharmaceuticals. It distributes products and solutions in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders, Central Nervous System, Vaccines, Multi-Specialty, and primary care. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Cremaffin Plus (Constipation), Pankreoflat (indigestion), Brufen P (fever), and Duvadilan (preterm labor). It offers various products under brands such as Similac, PediaSure, Pedialyte, EleCare, Ensure, and Glucerna.

Employees

3,814

Sector

Pharmaceuticals

Calendar

25/07 - Détachement de for final dividend

More about the company